WHO- IVI 공동 심포지움

BtoB 1

WHO- IVI 공동 심포지움

09:00 ~ 18:00 / 09:00 ~ 12:00 로즈 5F

설명
이 심포지엄의 목적은 동물 및 인간의 MERS-CoV 백신 개발 현황을 업데이트하고 백신 연구 및 개발을 가속화하기 위한 활동을 확인하고 우선 순위를 정하는 것입니다. 공유된 정보와 논의된 향후 계획을 취합하여 MERS-CoV 백신에 대한 WHO R&D 청사진 로드맵을 업데이트하는 데 사용할 예정입니다.
일시
6월 26일(화) 09:00 ~ 18:00 / 6월 27일(수) 09:00 ~ 12:00
장소
로즈 5F 행사장 안내

상세 일정

시간 발표제목 발표자료
WHO-IVI Joint Symposium
09:00~09:10(10')

Congratulatory Remarks

Sun-Hee Lee / NIFDS

-
09:10~09:20(10')

Opening Remarks

Maria Van Kerkhove / WHO

-
[Session 1] MERS update and laboratory evaluation | Chair : In-Kyu Yoon (IVI)
09:20~10:00(40')

Update of global MERS situation and WHO R&D Roadmap for MERS-CoV

Maria Van Kerkhove / WHO

-
10:00~10:30(30')

WHO Collaborative study to compare MERS-CoV Serological assays

Ruth Harvey / NIBSC

-
10:30~11:00(30')

Generation and spread of mutant MERS-CoV with reduced affinity to CD26 potentially driven by neutralizing antibodies during the south Korean outbreak

Nam Hyuk Cho / SNU

-
11:00~11:20(20')

Coffee Break

-
[Session 2] Animal vaccine development | Chair : Filip Claes (FAO) & Gounalan Pavade (OIE)
11:20~11:50(30')

Overview of MERS-CoV in animals, vaccine options, and update of Doha/Oman Declarations

Filip Claes / FAO

-
11:50~12:20(30')

Challenges in dromedary vaccine development for MERS-CoV

Gounalan Pavade / OIE

-
Updates from dromedary vaccine developers
12:20~12:45(25')

MVA-based dromedary MERS-CoV vaccine

Bart Haagmans / Erasmus

-
12:45~13:10(25')

Evaluation of Adenoviral Vector-based MERS-CoV vaccine in dromedary camels in Saudi Arabia

Naif Khalaf Alharbi / KAIMRC

-
14:10~14:35(25')

Animals models for MERS countermeasure development

Chien-Te Kent Tseng / UTMB Health

-
14:35~15:05(30')

Panel Discussion: Animal vaccine development

Moderator: Filip Claes / FAO
Panelists: Naif Khalaf Alharbi / KAIMRC
Bart Haagmans / Erasmus
Gounalan Pavade / OIE

-
[Session 3] Human vaccine development | Chair : Youngmee Jee (KCDC) & Kyong-Ran Peck (SMC)
15:05~15:30(25')

WHO R&D Blueprint for action to prevent epidemics

Marie-Pierre Preziosi / WHO by Phone

-
15:30~15:55(25')

MERS-CoV vaccine landscape

In-Kyu Yoon / IVI

-
15:55~16:15(20')

Coffee Break

-
Updates from MERS-CoV vaccine developers
16:15~16:40(25')

DNA vaccine (GLS-5300) against the MERS-CoV : results of a Phase I study

Joel Maslow / GeneOne

-
16:40~17:05(25')

Safety and Immunogenicity of the candidate MERS-CoV vaccine ChAdOx1 MERS - Updates from a phase I, first-in-human, dose-escalation trial

Pedro Folegatti / Jenner

-
17:05~17:30(25')

Development of MVA candidate vaccines against MERS

Gerd Sutter / LMU

-
17:30~18:00(30')

Panel Discussion : Human Vaccine Development

Moderator: Youngmee Jee (KCDC) & Kyong-Ran Peck (SMC)
Panelists: Pedro Folegatti / Jenner
Joel Maslow / GeneOne
Katrin Ramsauer / Themis
Gerd Sutter / LMU
In-Kyu Yoon / IVI

-
June 27       [Session 4] Next steps | Chair : Maria Van Kerkhove (WHO)
09:00~09:20(20')

The role of CEPI in MERS-CoV vaccine development

Melanie Saville / CEPI

-
09:20~09:40(20')

Regulatory pathways for MERS-CoV vaccine

Alireza Khadem / WHO

-
09:40~10:00(20')

Expedited pathways for vaccines in Korea

Dokeun Kim / MFDS

-
10:00~10:30(30')

Coffee Break

-
10:30~11:30(60')

Panel Discussion: MERS-CoV vaccine use from country perspective

Moderators: Maria Van Kerkhove (WHO) & Gounalan Pavade (OIE)
Panelists: Ali Abdul-Al / KSA
Farida Al Hosani / UAE
Mohammed Hamad Al-Thani / Qatar
Rome Buathong / Thailand

-
11:30~12:00(30')

Conclusions and next steps

Maria Van Kerkhove (WHO) / In-Kyu Yoon (IVI)

-